Literature DB >> 11138927

Neuroserpin mutation S52R causes neuroserpin accumulation in neurons and is associated with progressive myoclonus epilepsy.

M Takao1, M D Benson, J R Murrell, M Yazaki, P Piccardo, F W Unverzagt, R L Davis, P D Holohan, D A Lawrence, R Richardson, M R Farlow, B Ghetti.   

Abstract

Mutations in the Neuroserpin gene have been reported to cause familial presenile dementia. We describe a new family in which the S52R Neuroserpin mutation is associated with progressive myoclonus epilepsy in 2 siblings. The proband presented myoclonus and epilepsy at age 24, his brother and mother presented a similar disorder when they were 25. A clinical diagnosis of progressive myoclonus epilepsy was made on the proband and his brother. Skin and liver biopsies did not reveal the presence of cytological alterations in the proband. His neurological status worsened over the subsequent 19 yr during which he became demented and had uncontrollable seizures. He died at 43 yr of age from aspiration pneumonia. Neuropathologically, eosinophilic bodies, which were positive for periodic acid-Schiff and immunoreactive with antibodies against human neuroserpin, were present in the perikarya and cell processes of the neurons. They were found in large numbers in the cerebral cortex and substantia nigra and to a lesser extent, in most subcortical gray areas, spinal cord, and dorsal root ganglia. By electron microscopy, the intracytoplasmic bodies were contained within the membranes of the rough endoplasmic reticulum. Occasionally neuroserpin immunopositivity was seen throughout the cytoplasm, even without the presence of well-defined bodies. Our study characterizes for the first time the neuropathologic phenotype associated with hereditary progressive myoclonus epilepsy caused by the S52R Neuroserpin mutation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11138927     DOI: 10.1093/jnen/59.12.1070

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  20 in total

Review 1.  Tissue plasminogen activator and seizures: a clot-buster's secret life.

Authors:  Robert Pawlak; Sidney Strickland
Journal:  J Clin Invest       Date:  2002-06       Impact factor: 14.808

2.  Tissue plasminogen activator, neuroserpin, and seizures.

Authors:  Annamaria Vezzani
Journal:  Epilepsy Curr       Date:  2005 Jul-Aug       Impact factor: 7.500

3.  Accumulation of mutant neuroserpin precedes development of clinical symptoms in familial encephalopathy with neuroserpin inclusion bodies.

Authors:  Giovanna Galliciotti; Markus Glatzel; Jochen Kinter; Serguei V Kozlov; Paolo Cinelli; Thomas Rülicke; Peter Sonderegger
Journal:  Am J Pathol       Date:  2007-04       Impact factor: 4.307

Review 4.  Protein misfolding and the serpinopathies.

Authors:  Didier Belorgey; Peter Hägglöf; Susanna Karlsson-Li; David A Lomas
Journal:  Prion       Date:  2007-01-06       Impact factor: 3.931

5.  Identification of a novel targeting sequence for regulated secretion in the serine protease inhibitor neuroserpin.

Authors:  Shoji Ishigami; Maria Sandkvist; Foon Tsui; Elizabeth Moore; Timothy A Coleman; Daniel A Lawrence
Journal:  Biochem J       Date:  2007-02-15       Impact factor: 3.857

6.  The aggregation-prone intracellular serpin SRP-2 fails to transit the ER in Caenorhabditis elegans.

Authors:  Richard M Silverman; Erin E Cummings; Linda P O'Reilly; Mark T Miedel; Gary A Silverman; Cliff J Luke; David H Perlmutter; Stephen C Pak
Journal:  Genetics       Date:  2015-03-18       Impact factor: 4.562

7.  HuD binds to three AU-rich sequences in the 3'-UTR of neuroserpin mRNA and promotes the accumulation of neuroserpin mRNA and protein.

Authors:  Ana Cuadrado; Cristina Navarro-Yubero; Henry Furneaux; Jochen Kinter; Peter Sonderegger; Alberto Muñoz
Journal:  Nucleic Acids Res       Date:  2002-05-15       Impact factor: 16.971

Review 8.  The potential of antiseizure drugs and agents that act on novel molecular targets as antiepileptogenic treatments.

Authors:  Rafal M Kaminski; Michael A Rogawski; Henrik Klitgaard
Journal:  Neurotherapeutics       Date:  2014-04       Impact factor: 7.620

9.  Phenotypic variability in three families with valosin-containing protein mutation.

Authors:  S Spina; A D Van Laar; J R Murrell; R L Hamilton; J K Kofler; F Epperson; M R Farlow; O L Lopez; J Quinlan; S T DeKosky; B Ghetti
Journal:  Eur J Neurol       Date:  2012-08-20       Impact factor: 6.089

10.  Regulation of seizure spreading by neuroserpin and tissue-type plasminogen activator is plasminogen-independent.

Authors:  Manuel Yepes; Maria Sandkvist; Timothy A Coleman; Elizabeth Moore; Jiang-Young Wu; David Mitola; Thomas H Bugge; Daniel A Lawrence
Journal:  J Clin Invest       Date:  2002-06       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.